Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic screening for CSF1R variants in patients with dementia, parkinsonism, and multiple sclerosis.

Neurologia i neurochirurgia polska·2026
Same author

Clinical Phenotype Comparison in Polish Patient Cohorts with and Without Molecular Diagnosis of Dystonia.

Journal of clinical medicine·2026
Same author

Clinical and neuropathological analysis of the most common CSF1R p.Ile794Thr mutation.

Neurologia i neurochirurgia polska·2026
Same author

Adding continuous infusion therapies after bilateral subthalamic deep brain stimulation in advanced Parkinson's disease: clinical outcomes and quality of life assessment in a case series.

Neurologia i neurochirurgia polska·2026
Same author

Phosphorylated ubiquitin is a secondary messenger and an epigenetic mark mediating mitochondria to nucleus signaling.

bioRxiv : the preprint server for biology·2026
Same author

The history of Mayo Clinic Faculty Teaching Courses in Poland.

Neurologia i neurochirurgia polska·2026
Same journal

The First Autopsy-Proven Case of CSF1R-Related Leukoencephalopathy Harboring the p.Cys774Arg Mutation.

Neuropathology : official journal of the Japanese Society of Neuropathology·2026
Same journal

Molecular Evidence for Early Tertiary Lymphoid Structure Formation in Lymphoplasmacyte-Rich Meningioma: A Comment on the Report by Shintaku et al.

Neuropathology : official journal of the Japanese Society of Neuropathology·2026
Same journal

Primary Gliosarcoma With Mesenchymal Differentiation Resembling Follicular Dendritic Cell Sarcoma.

Neuropathology : official journal of the Japanese Society of Neuropathology·2026
Same journal

Lymphoplasmacyte-Rich Meningioma: Possible Formation of Intratumoral "Tertiary Lymphoid Structures".

Neuropathology : official journal of the Japanese Society of Neuropathology·2026
Same journal

An Autopsy Case of a Patient With Corticobasal Degeneration and a History of Acute Restlessness and Stupor.

Neuropathology : official journal of the Japanese Society of Neuropathology·2026
Same journal

Transferrin Receptor 1 Overexpression Drives Proliferation and Ferroptosis Sensitivity in Glioblastoma: A Potential Therapeutic Vulnerability.

Neuropathology : official journal of the Japanese Society of Neuropathology·2026
See all related articles
  1. Home
  3. Colony Stimulating Factor-1 Receptor-related Disorder Treated With Ilunazebart.
  1. Home
  3. Colony Stimulating Factor-1 Receptor-related Disorder Treated With Ilunazebart.

Related Experiment Video

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Colony Stimulating Factor-1 Receptor-Related Disorder Treated With Ilunazebart.

Lukasz Milanowski1,2, Delaney Liskey3,4, Audrey J Strongosky1

  • 1Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.

Neuropathology : Official Journal of the Japanese Society of Neuropathology
|June 23, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

This case study of Colony stimulating factor-1 receptor-related disorder (CSF1R-RD) found that the TREM2 agonist iluzanebart did not improve clinical, radiological, or neuropathological outcomes in a patient with advanced disease.

Keywords:
CSF1R‐related disorderTREM2iluzanebartleukoencephalopathyneurodegenerative disease

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Experiment Videos

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
07:20

Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation

Published on: January 14, 2011

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Area of Science:

  • Neuroscience
  • Genetics
  • Pathology

Background:

  • Colony stimulating factor-1 receptor-related disorder (CSF1R-RD) is a rare, autosomal dominant neurodegenerative disease characterized by microglial dysfunction and white matter degeneration.
  • Therapeutic strategies targeting microglial pathways, such as TREM2 activation, are being explored to counteract impaired CSF1R signaling.